An update on the revision of the EU legislation on blood, tissues and cells

The European Commission’s two stakeholder consultations on the Revision of the Blood, Tissue and Cells (BTC) Directive closed on the 15th of April 2021. The public consultation provided an opportunity to give feedback on policy options proposed by the Commission to address gaps in the existing Directive. A total of 214 stakeholders replied to the general consultation, and 160 organisations replied to the targeted consultation. Stakeholder input is  currently being analysed by the European Commission, and a report will soon be available. Further, a first external study has been initiated to support the Impact Assessment, and will be led by a team of three BTC experts. The publication of the Commission’s Impact Assessment is expected at the end of 2021, alongside the proposal. More information can be found here.

Stay up to date

    © CSL 2026

    Blood & Beyond is a multi-stakeholder initiative funded by CSL, involving experts from the fields of haematology, transfusion medicine, anaesthesiology, patient blood management, nursing, patient advocacy, health economics, and hospital management, with support from policymakers committed to driving improvements in this area. The aim of the initiative is to raise awareness of the importance of good blood health and of the impact of anaemia on patients, healthcare systems and society at large, with the overarching goal to help advance policies and practices that improve patient outcomes by supporting patient-centricity in anaemia prevention, diagnosis, and management through patient blood management (PBM) and innovation.

    Contact

    For further information and queries, please contact the Blood and Beyond Secretariat: javier.lopezpanos@dgagroup.com

    Privacy Preference Center